If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02467335","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":"true"},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"Non-randomized","arm_groups":[{"arm_group_label":"Healthy Subjects","arm_group_description":"Healthy subjects will receive a single, oral dose of BMS-663068 on Day 1.","arm_type":"Active Comparator"},{"arm_group_label":"Hepatic Impaired Subjects - Mild Rating","arm_group_description":"Mildly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.","arm_type":"Active Comparator"},{"arm_group_label":"Hepatic Impaired Subjects - Moderate Rating","arm_group_description":"Moderately impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.","arm_type":"Active Comparator"},{"arm_group_label":"Hepatic Impaired Subjects - Severe Rating","arm_group_description":"Severly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.","arm_type":"Active Comparator"}],"assignment":"Single Group Assignment","brief_summary":"A single oral dose study in subjects with hepatic impairment and healthy control subjects. Subjects will stay at the clinical facility where interval blood samplings will be obtained and examined for drug effect.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects with Hepatic Impairment Compared to Healthy Subjects","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:33:57","criteria":"Inclusion Criteria: - Males and females, ages 18 to 70 years, inclusive - BMI: 18.5 to 38 kg/m2 - Body weight great or equal to 45.5 kg - Subjects with hepatic impairment - Subjects with hepatic impairment must be on a stable dose of medication and/or treatment regimen - Healthy subjects to the extent possible matched to the first four subjects with hepatic impairment with regard to age, body weight, and sex, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations Exclusion Criteria: - Any major surgery within 4 weeks of study drug administration - Donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma only) - Subject has required additional medication for hepatic encephalopathy within 12 months (6 months for severe hepatic impairment) prior to dosing - Presence of severe ascites or edema in subjects, as judged by the PI","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"52","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"192218e2-3462-505a-bd05-d23f0bde5cff","internal":{"content":null,"contentDigest":"f58eb761f4794de867354cbed70fc1d5","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Males and females, ages 18 to 70 years, inclusive - BMI: 18.5 to 38 kg/m2 - Body weight great or equal to 45.5 kg - Subjects with hepatic impairment - Subjects with hepatic impairment must be on a stable dose of medication and/or treatment regimen - Healthy subjects to the extent possible matched to the first four subjects with hepatic impairment with regard to age, body weight, and sex, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations Exclusion Criteria: - Any major surgery within 4 weeks of study drug administration - Donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma only) - Subject has required additional medication for hepatic encephalopathy within 12 months (6 months for severe hepatic impairment) prior to dosing - Presence of severe ascites or edema in subjects, as judged by the PI","interventions":[{"arm_group_label":"Healthy Subjects","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Hepatic Impaired Subjects - Moderate Rating","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Hepatic Impaired Subjects - Severe Rating","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Hepatic Impaired Subjects - Mild Rating","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"}],"interventional_subtype":"Basic Science","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":[],"last_follow_up_date":"10/03/2015 00:00:00","links":[],"locations":[{"City":"Hamilton","Latitude":"40.2276834","CountryDisplay":"United States","Longitude":"-74.6576091","Name":"GSK Investigational Site","StateDisplay":"New Jersey","PostalCode":"08690","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"70 years","maximum_age":"70","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:44:48","number_of_arms":"4","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects with Hepatic Impairment Compared to Healthy Subjects","org_study_id":"206280","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"1","primary_compl_date":"10/03/2015 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"The effects of hepatic impairment on the single-dose peak plasma concentration Cmax of BMS-626529 (metabolite).","outcome_time_frame":"5 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"The effects of hepatic impairment on the single-dose area under the plasma concentration versus time curve AUC (INF) of BMS-626529 (metabolite).","outcome_time_frame":"5 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"The effects of hepatic impairment on the single-dose area under the plasma concentration versus time curve AUC (0-T) of BMS-626529 (metabolite).","outcome_time_frame":"5 days","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"AI438-053","id_type":"Other Identifier","id_domain":"Bristol-Myers Squibb"}],"secondary_outcomes":[{"outcome_description":"Adverse events will be arranged by system organ class, preferred term and hepatic function group. In addition, electrocardiogram readings will be summarized by time point relative to hepatic function group, and investigator-identified abnormalities, if present, will be listed.","outcome_measure":"The safety and tolerability of a 600-mg single dose of BMS-663068 in subjects with hepatic impairment and in healthy subjects through analysis of adverse events.","outcome_time_frame":"5 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"The relationship between the Child-Pugh classification (including its components) as well as liver function tests and BMS-626529 profile PK parameters.","outcome_time_frame":"5 days","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GlaxoSmithKline"]},"start_date":"01/29/2015 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":false}},"pageContext":{"studyId":"206280"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}